首页> 外文OA文献 >Classification of Non-Demented Patients Attending a Memory Clinic using the New Diagnostic Criteria for Alzheimer's Disease with Disease-Related Biomarkers.
【2h】

Classification of Non-Demented Patients Attending a Memory Clinic using the New Diagnostic Criteria for Alzheimer's Disease with Disease-Related Biomarkers.

机译:使用与疾病相关的生物标记物的阿尔茨海默氏病新诊断标准对参加记忆诊所的非骨水泥患者进行分类。

摘要

Background: New diagnostic criteria for predemential Alzheimer's disease (AD) advocate the use of biomarkers. However, the benefit of using biomarkers has not been clearly demonstrated in clinical practice. Objective: To investigate whether a combination of biomarkers may be helpful in classifying a population of non-demented patients attending a Memory Clinic. Methods: Sixty non-demented patients were compared with 31 healthy elderly subjects. All subjects underwent a neuropsychological examination, brain 3T magnetic resonance imaging, and [F18]-fluorodeoxyglucose and [F18]-flutemetamol positron emission tomography. According to their performance on memory, language, executive, and visuo-spatial domains, the patients were classified as mild cognitive impairment (amnestic, non-amnestic, single, or multiple domain) or subjective cognitive impairment. Patients were then classified according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, using the normalized mean hippocampal volume (Freesurfer), [F18]-FDG PALZAD, and [F18]-flutemetamol standard uptake value ratio (SUVr) (cut-off at the 10th percentile of controls). The standard of truth was the clinical status at study entry (patient versus control). Results: The sensitivity/specificity of the clinical classification was 65/84%. The NIA-AA criteria were applicable in 85% of patients and 87% of controls. For biomarkers the best sensitivity (72%) at a fixed specificity of 84% was achieved by a combination of the three biomarkers. The clinical diagnosis was reconsidered in more than one third of the patients (42%) as a result of including the biomarker results. Conclusions: Application of the new NIA-AA AD diagnostic criteria based on biomarkers in an unselected sample of non-demented patients attending a Memory Clinic was useful in allowing for a better classification of the subjects.
机译:背景:痴呆前阿尔茨海默氏病(AD)的新诊断标准提倡使用生物标志物。但是,在临床实践中尚未明确证明使用生物标志物的益处。目的:探讨生物标记物的组合是否有助于对参加记忆诊所的非痴呆患者进行分类。方法:将60名非痴呆患者与31名健康老年患者进行比较。所有受试者均接受了神经心理学检查,大脑3T磁共振成像以及[F18]-氟脱氧葡萄糖和[F18]-氟他莫尔正电子发射断层显像。根据他们在记忆,语言,执行力和视觉空间领域的表现,将患者分类为轻度认知障碍(遗忘,非遗忘,单或多领域)或主观认知障碍。然后根据美国国家老年痴呆症协会(NIA-AA)的标准对患者进行分类,使用标准化的平均海马体积(Freesurfer),[F18] -FDG PALZAD和[F18]-氟美他莫标准摄取值比(SUVr )(截止到控件的第10个百分位数)。真实的标准是研究进入时的临床状态(患者与对照组)。结果:临床分类的敏感性/特异性为65/84%。 NIA-AA标准适用于85%的患者和87%的对照。对于生物标志物,三种生物标志物的组合在固定特异性为84%时获得了最佳灵敏度(72%)。由于纳入了生物标志物结果,超过三分之一的患者(42%)重新考虑了临床诊断。结论:在未选择的非痴呆患者的参加记忆诊所的样本中,基于生物标记物的新NIA-AA AD诊断标准的应用有助于更好地对受试者进行分类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号